Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: revenue of $3.6M beat the $2.2M expectation by 64.44% following the successful US launch of AVLAYAH™. While loss from operations of -$130.5M was narrower than the -$141.2M consensus, GAAP EPS of -$0.68 missed the -$0.57 estimate due to $5.9M in non-cash interest expenses related to the Royalty Pharma agreement. Post-quarter, the $195M sale of a Priority Review Voucher (PRV) significantly strengthens the balance sheet, providing a primary catalyst for H2 FY26.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Denali Therap(DNLI) the Revenue is 3.604 M (--%), Beat estimate;the EBIT is -130.54 M (+3.28%), Beat estimate;the EPS is -0.68 (+5.56%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITExceed expectations
-0.13B3.28%
-0.14B4.59%
+0.01B7.87%
EPSMiss expectations
-0.685.56%
-0.565121.51%
-0.114915.95%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf